MedPath
HSA Product

SKYCELLFLU QUADRIVALENT PREFILLED SYRINGE 0.5ML

Product approved by Health Sciences Authority (SG)

Basic Information

SKYCELLFLU QUADRIVALENT PREFILLED SYRINGE 0.5ML

INJECTION

Regulatory Information

SIN15781P

August 16, 2019

Prescription Only

Therapeutic

INTRAMUSCULAR

August 10, 2023

May 30, 2025

XJ07BB02

Company Information

SK bioscience Co., Ltd. (L House)

AJ BIOLOGICS PTE. LTD.

AJ BIOLOGICS PTE. LTD.

Active Ingredients

Detailed Information

Contraindications

Under 【 **Precautions for use**】 **1\. Do not administer SKYCellflu Quadrivalent® to the following individuals.** If deemed necessary after a medical interview and visual inspection, examine the subject’s health condition further using methods such as auscultation and percussion. Do not administer the vaccine to subjects with following conditions. As an exception, the vaccine may be administered to subjects who are at risk of possible influenza infection and determined to have no likelihood of developing serious disabilities due to the administration of the vaccine. 01. Hypersensitivity reaction to active ingredient and/or any other ingredient (including formalin) in SKYCellflu Quadrivalent® 02. Febrile disease or acute infection 03. History of severe hypersensitivity reaction and/or convulsive symptom to previous influenza vaccination 04. History of Guillain-Barre syndrome or other neurological disorder within 6 weeks of previous influenza vaccination 05. Fever 06. Cardiovascular disease, renal disease, or hepatic disease in acute, exacerbation, or active phase 07. Acute respiratory disease or other active infection 08. History of anaphylaxis reaction to any ingredient in SKYCellflu Quadrivalent® 09. History of suspected allergic reaction, including systemic rash, to previous vaccination 10. Other medical conditions that are diagnosed to be inappropriate for administration of SKYCellflu Quadrivalent® vaccine.

Indication Information

【 **Indications**】 Active immunization for the prevention of influenza disease caused by influenza virus subtypes A and type B contained in the vaccine, for adults and children 3 years of age and older. The use of SKYCellflu Quadrivalent® should be based on official recommendations.

© Copyright 2025. All Rights Reserved by MedPath